{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-067940","form_type":"8-K","ticker":"IOVA","cik":"0001425205","company_name":"IOVANCE BIOTHERAPEUTICS, INC.","filed_at":"2025-07-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.958918+00:00","generated_at":"2026-05-18T06:28:02.984938+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Iovance appoints Corleen Roche as CFO effective August 6, 2025","bullets":["Corleen Roche, former CFO of CG Oncology and Immunome, replaces Matthew Rosinack as Principal Financial Officer.","Base salary of $600,000, one-time sign-on bonus of $50,000, and annual bonus target of 45% of base salary.","Receives 300,000 stock options and 150,000 RSUs, each vesting over 4 years with quarterly vesting after first anniversary.","Severance upon qualifying termination includes 12 months salary, pro-rated bonus, and accelerated equity vesting."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-067940","json":"https://secwatch.observer/filing/0001104659-25-067940.json","markdown":"https://secwatch.observer/filing/0001104659-25-067940.md","text":"https://secwatch.observer/filing/0001104659-25-067940.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1425205/000110465925067940/0001104659-25-067940-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1425205/000110465925067940/tm2520947d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T06:28:02.984938+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}